A little more than a year after Abraxane gained FDA approval as a treatment for breast cancer, its developer, Abraxis BioScience Inc., has signed a co-promotion agreement with AstraZeneca plc, essentially doubling the promotional investment of the product. (BioWorld Today)

Seven years after forming a joint venture for cancer immunotherapies based on prostate specific membrane antigen, Cytogen Corp. agreed to sell its 50 percent ownership to partner Progenics Pharmaceuticals Inc. in a deal potentially worth more than $65 million. (BioWorld Today)

Endo Pharmaceuticals dropped out as SkyePharma plc's North American development partner for Propofol IDD-D, leaving the future of the anesthetic in limbo as the London-based company decides the next steps. (BioWorld Today)